Evidence lead: Top-three record · Large request-volume cohort
Humana: One of the ten largest authorization workloads
The 1,450,000 recorded requests place this contract in the highest-volume tier. Its request-volume rank is #2 of 37. Volume shows the denominator behind approvals and denials; it is not a measure of plan quality, membership, benefit breadth, price, or future coverage decisions.
Top-three record · Large request-volume cohort
One of the ten largest authorization workloads
The 1,450,000 recorded requests place this contract in the highest-volume tier. Its request-volume rank is #2 of 37. Volume shows the denominator behind approvals and denials; it is not a measure of plan quality, membership, benefit breadth, price, or future coverage decisions.
Ranks seven through ten · Higher denial-rate cohort
A top-ten denial rate in this source set
Humana's 10.4% denial rate is in the highest group of the comparison. The exact rank is #7 of 37. This is aggregate prior-authorization activity for the reporting window, not a probability that a particular service, drug, or beneficiary request will be denied.
Ranks eleven through fifteen · Upper-middle appeal uptake
Appeal filing exceeded most contract records
The 22,620 filed appeals represent 15.0% of denied requests. That is rank #11 of 37 for filing share. The ratio reports aggregate activity; it cannot reveal why an appeal was or was not filed, whether the underlying cases were comparable, or what happened outside the reporting window.
Ranks twenty-one through twenty-five · Lower-middle overturn cohort
Appeal overturns sat below the table midpoint
This contract records a 68.0% overturn rate among filed appeals. Its overturn-rate rank is #24 of 37. The denominator is filed appeals, not all authorization requests. The percentage therefore describes reviewed appeals and must not be read as an individual outcome forecast.
Ranks twenty-one through twenty-five · Lower-middle reversal reach
Reversals covered a below-median share of denials
The 15,382 recorded reversals amount to 10.2% of this contract's denied requests. The cross-contract rank is #24 of 37. This derived measure combines appeal filing and outcome, so it supplies scale context but does not identify clinical reasons, administrative errors, or coverage rules.